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Luke B Hesson* and Robyn L WardDear Editor,
The July-August 2014 issue of Clinical Epigenetics fea-
tured a research article describing PTEN promoter hyper-
methylation in multiple myeloma by Piras et al. [1]. The
importance of the PTEN gene has resulted in significant
efforts to identify sequence, expression and methylation
changes in cancer. Piras et al. concluded that PTEN
hypermethylation occurred in a subset of multiple mye-
loma cases but that hypermethylation did not correlate
with reduced gene expression or clinical parameters. The
PTEN mRNA shares 97.8% sequence identity with a
pseudogene known as PTENP1. A 921-bp region of the
promoters of these genes is also 91% identical. Conse-
quently, careful consideration of assay design is required
to avoid amplification of PTENP1 rather than PTEN se-
quences. However, the method used by Piras et al. for
measuring PTEN mRNA did not distinguish between
these homologues, despite numerous studies showing that
PTENP1 mRNA is ubiquitously expressed in both normal
and cancer specimens [2-5]. Furthermore, previous studies
have demonstrated that apparent methylation of the
PTEN promoter is likely attributable to the non-specific
amplification of the highly homologous PTENP1 gene
[6,7]. We have shown that the only reliable method for
distinguishing between PTEN and PTENP1 promoter
methylation is single-molecule bisulfite sequencing that
utilizes sequence differences between the two genes to
separately analyze individual promoter molecules [6,8].
These methodological challenges make comparisons be-
tween methylation and expression impossible when using
assays that do not reliably discriminate between PTEN
and PTENP1, and also negate the value of correlating
these features with clinicopathological characteristics.
The challenges posed by sequence homology with pseu-
dogenes are by no means particular to the PTEN gene.
For example, the DNA mismatch repair gene PMS2
shares >95.2% sequence identity with at least six other* Correspondence: l.hesson@unsw.edu.au
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unless otherwise stated.genes (PMS2CL, PMS2L2, PMS2P4, PMS2P5, PMS2P1
and PMS2P11) making analysis of the PMS2 CpG island
promoter region particularly challenging.
In light of the recent manuscript by Piras et al., it is
necessary to highlight the importance of rigorous meth-
odology when investigating DNA methylation changes in
cancer, especially concerning genes with homologues or
pseudogenes such as PTEN.
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